Ubiquitin Drug Discovery & Diagnostics 2009 - First Annual Conference
Affiliations
- PMID: 19943215
Item in Clipboard
Ubiquitin Drug Discovery & Diagnostics 2009 - First Annual Conference
IDrugs.
2009 Dec.
Abstract
The Ubiquitin Drug Discovery & Diagnostics conference, held in Philadelphia, included topics covering new therapeutic developments in the field of ubiquitin drug research. This conference report highlights selected presentations on emerging ubiquitin targets in oncology and on proteasome inhibitor therapy for the treatment of multiple myeloma. Investigational drugs discussed include MLN-4924 and MLN-9708 (both Millennium Pharmaceuticals Inc), P-005091 (Progenra Inc), CEP-18770 (Cephalon Inc) and carfilzomib (Proteolix Inc).
Similar articles
-
AACR-NCI-EORTC--21st International Symposium. Molecular targets and cancer therapeutics--Part 2.IDrugs. 2010 Jan;13(1):10-2. IDrugs. 2010. PMID: 20024839
-
AACR-NCI-EORTC--21st International Symposium. Molecular targets and cancer therapeutics--Part 1.IDrugs. 2010 Jan;13(1):7-9. IDrugs. 2010. PMID: 20024838
-
International Drug Discovery Science and Technology--BIT's Seventh Annual Congress.IDrugs. 2010 Jan;13(1):23-5. IDrugs. 2010. PMID: 20024843
-
Highlights in experimental therapeutics.Cancer Lett. 2007 Jan 8;245(1-2):11-21. doi: 10.1016/j.canlet.2006.03.012. Epub 2006 May 2. Cancer Lett. 2007. PMID: 16647200 Review.
-
Proteasome inhibition in multiple myeloma.Eur J Cancer. 2006 Jul;42(11):1623-39. doi: 10.1016/j.ejca.2006.02.015. Epub 2006 Jul 3. Eur J Cancer. 2006. PMID: 16820291 Review.
Cited by
-
Characterisation of the Trichinella spiralis deubiquitinating enzyme, TsUCH37, an evolutionarily conserved proteasome interaction partner.PLoS Negl Trop Dis. 2011 Oct;5(10):e1340. doi: 10.1371/journal.pntd.0001340. Epub 2011 Oct 4. PLoS Negl Trop Dis. 2011. PMID: 22013496 Free PMC article.